Bariatric Surgery's Enduring Role Amidst Rising GLP-1 RA Popularity

The global prevalence of obesity continues its alarming rise, particularly stage III obesity in North America, leading to severe health impairments. Accumulation of excess adipose tissue (body fat) significantly increases the risk of cardiovascular disease, a primary driver of increased mortality. While lifestyle modifications are foundational, achieving sustainable weight loss and improved health outcomes often necessitates advanced interventions like pharmacotherapy and bariatric surgery. This review addresses how bariatric surgery maintains its critical position as an effective treatment strategy in the evolving landscape dominated by novel glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

The review highlights that bariatric surgery consistently demonstrates superior long-term efficacy for weight loss and resolution of obesity-related comorbidities compared to current pharmacotherapies. Despite this, its real-world impact is significantly hampered by low acceptability and limited accessibility, rendering it an underutilized treatment option for many eligible individuals. Conversely, the adoption of GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide and tirzepatide, has become widespread, showing significant weight loss and improved health outcomes in numerous randomized controlled trials. However, the practical effectiveness of GLP-1 RAs in broader populations faces substantial hurdles, including high costs and tolerability issues that can lead to treatment discontinuation. The authors conclude that, even with the advent of highly effective GLP-1 RAs, bariatric surgery is projected to retain its essential and distinct role in the comprehensive management of obesity, particularly for patients with severe obesity or those who do not achieve adequate results with pharmacotherapy.